The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma: Long-term follow-up of the GERCOR NEONIPIGA phase II study.
 
Thomas Samaille
Consulting or Advisory Role - Merck Serono
Travel, Accommodations, Expenses - Merck Serono
 
Julie Henriques
No Relationships to Disclose
 
David Tougeron
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Incyte; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; Servier/Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; BMS; MSD; Novartis; Pierre Fabre; Sanofi; SERVIER; Takeda
Research Funding - BTG (Inst); Gilead Sciences (Inst); MSD (Inst); Pierre Fabre (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Pierre Fabre; Roche; SERVIER
 
Guillaume Piessen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Lilly; Elivie; MSD Oncology; Nestle health science; Stryker
Travel, Accommodations, Expenses - Elivie; medtronic; MSD Oncology
Other Relationship - elivie
(OPTIONAL) Uncompensated Relationships - Medtronic
 
Christelle de la Fouchardière
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daichi-Sankyo; Gilead Sciences; Incyte; Jazz Pharmaceuticals; MSD Oncology; Pierre Fabre; SERVIER; Takeda
Research Funding - Agenus (Inst); MSD (Inst); Pierre Fabre (Inst); Servier (Inst); Summit Therapeutics (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD Oncology; Pierre Fabre; SERVIER
 
Christophe Louvet
No Relationships to Disclose
 
Antoine Adenis
No Relationships to Disclose
 
Marine Jary
Consulting or Advisory Role - Amgen; Incyte
Speakers' Bureau - Pierre Fabre; SERVIER
Research Funding - Bayer (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; AstraZeneca; Ax'Perf; Bayer; BMSi; EXPERF; Merck; MSD; Pierre Fabre; Pierre Fabre; Roche; Sanofi; SERVIER
 
Marie-Line Garcia-Larnicol
No Relationships to Disclose
 
Romain Cohen
Honoraria - Amgen; AstraZeneca; BMS GmbH & Co. KG; Daiichi Sankyo Europe GmbH; Exeliom Biosciences; Merck Serono; MSD Oncology; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; Exeliom Biosciences; MSD Oncology
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Daiichi Sankyo Europe GmbH; MSD Oncology; SERVIER
 
Dewi Vernerey
Consulting or Advisory Role - AC BioScience; Apmonia Therapeutics; cellprothera; CURE51; Fondazione Smith Kline; GERCOR; HalioDx; INCYTE; INVECTYS; Janssen-Cilag; OSE Immunotherapeutics; Pfizer; Veracyte
Travel, Accommodations, Expenses - MSD
 
Jeremie Lefevre
Stock and Other Ownership Interests - Moon surgical
Honoraria - Braun Travacare; Intuitive Surgical; Provepharm
Consulting or Advisory Role - SafeHeal
Research Funding - SafeHeal; SafeHeal (Inst)
Travel, Accommodations, Expenses - Biom'up; SafeHeal
 
Magali Svrcek
No Relationships to Disclose
 
Thierry Andre
Honoraria - Bristol-Myers Squibb; Merck; Merck Serono; Roche; Sanofi; Seagen; SERVIER
Consulting or Advisory Role - Abbvie; Aptitude Health; Aptitude Health; Biocartis; Bristol-Myers Squibb; Exelixis; Gilead Sciences; GlaxoSmithKline; Lilly; Medicenna; MSD Oncology; Nimbus Therapeutics; Nordic Bioscience; Pfizer; Roche; Sanofi; Sanofi; Seagen; SERVIER; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squib; Bristol-Myers Squibb; Merck; MSD Oncology; Takeda
Other Relationship - Inspirna
(OPTIONAL) Uncompensated Relationships - Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group; ARCAD Foundation; ARCAD Foundation